Advertisement
Journal of Hepatology
EASL
Advanced searchSave search
Editorial| Volume 68, ISSUE 1, P10-12, January 2018

NAFLD and cancer: More cause for concern?

  • Peter Jepsen
    Correspondence
    Corresponding author. Address: Department of Hepatology and Gastroenterology, Aarhus University Hospital, Nørrebrogade 44, DK-8000 Aarhus C, Denmark. Tel.: +45 7846 2800; fax: +45 7846 2860.
    Affiliations
    Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark

    Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark
    Search for articles by this author
  • Federica Turati
    Affiliations
    Department of Clinical Sciences and Community Health, University of Milan, 20133 Milan, Italy
    Search for articles by this author
  • Carlo La Vecchia
    Affiliations
    Department of Clinical Sciences and Community Health, University of Milan, 20133 Milan, Italy
    Search for articles by this author
Published:October 20, 2017DOI:https://doi.org/10.1016/j.jhep.2017.10.008
NAFLD and cancer: More cause for concern?
Previous ArticleEarly TIPS for portal hypertensive related bleeding: Is resource or education the reason for failure to show clear survival benefit?
Next ArticleFatty liver and renal function impairment – Time for awareness?
      Non-alcoholic fatty liver disease (NAFLD) is likely to become the most prevalent liver disease in many countries,
      • Armstrong M.J.
      • Houlihan D.D.
      • Bentham L.
      • Shaw J.C.
      • Cramb R.
      • Olliff S.
      • et al.
      Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort.
      J Hepatol. 2012; 56: 234-240
      , 
      • Younossi Z.
      • Anstee Q.M.
      • Marietti M.
      • Hardy T.
      • Henry L.
      • Eslam M.
      • et al.
      Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention.
      Nat Rev Gastroenterol Hepatol. 2017; https://doi.org/10.1038/nrgastro.2017.109
      yet clinicians are struggling to determine exactly why they should care about NAFLD. Is it merely a bystander – a manifestation of the metabolic syndrome resulting in cardiovascular disease – or is it a liver disease in its own right?
      • Byrne C.D.
      • Targher G.
      NAFLD: A multisystem disease.
      J Hepatol. 2015; 62: S47-S64

      Linked Article

      • Association between non-alcoholic fatty liver disease and cancer incidence rate
        Journal of HepatologyVol. 68Issue 1
        • Preview
          Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases globally, with an estimated prevalence of 25.2%.1 NAFLD may progress to non-alcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma (HCC).1–3 Moreover, NAFLD is strongly associated with insulin resistance, the metabolic syndrome, diabetes, and cardiovascular disease, indicating that NAFLD is a multisystem disease with extrahepatic complications.4–6
        • Full-Text
        • PDF
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Hepatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Armstrong M.J.
        • Houlihan D.D.
        • Bentham L.
        • Shaw J.C.
        • Cramb R.
        • Olliff S.
        • et al.
        Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort.
        J Hepatol. 2012; 56: 234-240
        View in Article
        • Younossi Z.
        • Anstee Q.M.
        • Marietti M.
        • Hardy T.
        • Henry L.
        • Eslam M.
        • et al.
        Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention.
        Nat Rev Gastroenterol Hepatol. 2017; https://doi.org/10.1038/nrgastro.2017.109
        View in Article
        • Byrne C.D.
        • Targher G.
        NAFLD: A multisystem disease.
        J Hepatol. 2015; 62: S47-S64
        View in Article
        • Kim G.-A.
        • Lee H.C.
        • Choe J.
        • Kim M.-J.
        • Lee M.J.
        • Chang H.-S.
        • et al.
        Association between nonalcoholic fatty liver disease and cancer incidence rate.
        J Hepatol. 2018; 68: 140-146
        View in Article
        • Sørensen H.T.
        • Mellemkjær L.
        • Jepsen P.
        • Thulstrup A.M.
        • Baron J.
        • Olsen J.H.
        • et al.
        Risk of cancer in patients hospitalized with fatty liver: A Danish cohort study.
        J Clin Gastroenterol. 2003; 36: 356-359
        View in Article
        • Turati F.
        • Talamini R.
        • Pelucchi C.
        • Polesel J.
        • Franceschi S.
        • Crispo A.
        • et al.
        Metabolic syndrome and hepatocellular carcinoma risk.
        Br J Cancer. 2013; 108: 222-228
        View in Article
        • Welzel T.M.
        • Graubard B.I.
        • Zeuzem S.
        • El-Serag H.B.
        • Davila J.A.
        • McGlynn K.A.
        Metabolic syndrome increases the risk of primary liver cancer in the United States: A study in the SEER-Medicare database.
        Hepatology. 2011; 54: 463-471
        View in Article
        • Larsson S.C.
        • Wolk A.
        Overweight, obesity and risk of liver cancer: A meta-analysis of cohort studies.
        Br J Cancer. 2007; 97: 1005-1008
        View in Article
        • El-Serag H.B.
        • Hampel H.
        • Javadi F.
        The association between diabetes and hepatocellular carcinoma: A systematic review of epidemiologic evidence.
        Clin Gastroenterol Hepatol. 2006; 4: 369-380
        View in Article
        • La Vecchia C.
        • Negri E.
        • Decarli A.
        • Franceschi S.
        Diabetes mellitus and the risk of primary liver cancer.
        Int J Cancer. 1997; 73: 204-207
        View in Article
        • Pelucchi C.
        • Negri E.
        • Talamini R.
        • Levi F.
        • Giacosa A.
        • Crispo A.
        • et al.
        Metabolic syndrome is associated with colorectal cancer in men.
        Eur J Cancer. 2010; 46: 1866-1872
        View in Article
        • Rosato V.
        • Tavani A.
        • Gracia-Lavedan E.
        • Guino E.
        • Castano-Vinyals G.
        • Villanueva C.M.
        • et al.
        Type 2 diabetes, antidiabetic medications, and colorectal cancer risk: Two case-control studies from Italy and Spain.
        Front Oncol. 2016; 6: 210
        View in Article
        • la Vecchia C.
        • Giordano S.H.
        • Hortobagyi G.N.
        • Chabner B.
        Overweight, obesity, diabetes, and risk of breast cancer: Interlocking pieces of the puzzle.
        Oncologist. 2011; 16: 726-729
        View in Article
        • Rosato V.
        • Bosetti C.
        • Talamini R.
        • Levi F.
        • Montella M.
        • Giacosa A.
        • et al.
        Metabolic syndrome and the risk of breast cancer in postmenopausal women.
        Ann Oncol. 2011; 22: 2687-2692
        View in Article
        • European Association for the Study of the Liver
        • European Association for the Study of Diabetes
        • European Association for the Study of Obesity
        EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease.
        J Hepatol. 2016; 64: 1388-1402
        View in Article
        • Chalasani N.
        • Younossi Z.
        • Lavine J.E.
        • Charlton M.
        • Cusi K.
        • Rinella M.
        • et al.
        The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.
        Hepatology. 2017; https://doi.org/10.1002/hep.29367
        View in Article
        • Andersen P.K.
        • Geskus R.B.
        • de Witte T.
        • Putter H.
        Competing risks in epidemiology: Possibilities and pitfalls.
        Int J Epidemiol. 2012; 41: 861-870
        View in Article
        • Jepsen P.
        • Vilstrup H.
        • Andersen P.K.
        The clinical course of cirrhosis: The importance of multistate models and competing risks analysis.
        Hepatology. 2015; 62: 292-302
        View in Article
        • Bosetti C.
        • Turati F.
        • La Vecchia C.
        Hepatocellular carcinoma epidemiology.
        Best Pract Res Clin Gastroenterol. 2014; 28: 753-770
        View in Article
        • Dyson J.
        • Jaques B.
        • Chattopadyhay D.
        • Lochan R.
        • Graham J.
        • Das D.
        • et al.
        Hepatocellular cancer: The impact of obesity, type 2 diabetes and a multidisciplinary team.
        J Hepatol. 2014; 60: 110-117
        View in Article

      Article info

      Publication history

      Published online: October 20, 2017
      Accepted: October 13, 2017
      Received: October 11, 2017
      See Article, pages 140–146

      Identification

      DOI: https://doi.org/10.1016/j.jhep.2017.10.008

      Copyright

      © 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX